The offer was made pursuant to Sanofi's shelf registration statement filed with the US Securities and Exchange Commission on March 15, 2010.
Sanofi intends to use the net proceeds of the offering for general corporate purposes, including the repayment of existing borrowings.
BofA Merrill Lynch, Citigroup, Deutsche Bank and Natixis acted as joint-book running managers for the offering.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).